Nexthera Capital LP reduced its position in Immunomedics, Inc. (NASDAQ:IMMU) by 48.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 404,528 shares of the biopharmaceutical company’s stock after selling 387,578 shares during the period. Immunomedics comprises 1.2% of Nexthera Capital LP’s investment portfolio, making the stock its 23rd biggest position. Nexthera Capital LP’s holdings in Immunomedics were worth $6,537,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IMMU. Raymond James Financial Services Advisors Inc. increased its stake in Immunomedics by 11.4% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 1,473 shares in the last quarter. Calton & Associates Inc. purchased a new position in Immunomedics in the 4th quarter valued at approximately $135,000. Sapphire Star Partners LP purchased a new position in Immunomedics in the 4th quarter valued at approximately $323,000. SG Americas Securities LLC increased its stake in Immunomedics by 27.2% in the 3rd quarter. SG Americas Securities LLC now owns 26,350 shares of the biopharmaceutical company’s stock valued at $368,000 after purchasing an additional 5,631 shares in the last quarter. Finally, Virtus Fund Advisers LLC purchased a new position in Immunomedics in the 4th quarter valued at approximately $456,000. 74.52% of the stock is owned by hedge funds and other institutional investors.
Several research firms recently weighed in on IMMU. BidaskClub raised Immunomedics from a “hold” rating to a “buy” rating in a research note on Thursday, February 22nd. Zacks Investment Research downgraded Immunomedics from a “hold” rating to a “sell” rating in a research note on Saturday, February 17th. TheStreet raised Immunomedics from a “d” rating to a “c-” rating in a research note on Friday, February 9th. ValuEngine upgraded Immunomedics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Jefferies Group increased their target price on Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. Immunomedics currently has a consensus rating of “Buy” and an average price target of $19.00.
Immunomedics (NASDAQ:IMMU) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.09). The business had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $0.90 million. equities research analysts forecast that Immunomedics, Inc. will post -0.96 earnings per share for the current year.
In other Immunomedics news, Director David M. Goldenberg sold 17,729 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $17.09, for a total transaction of $302,988.61. Following the sale, the director now owns 1,774,285 shares in the company, valued at approximately $30,322,530.65. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David M. Goldenberg sold 20,000 shares of the stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $17.50, for a total value of $350,000.00. Following the sale, the director now owns 1,774,285 shares in the company, valued at approximately $31,049,987.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 77,729 shares of company stock worth $1,342,589. 14.80% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: “Immunomedics, Inc. (IMMU) Shares Sold by Nexthera Capital LP” was published by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.themarketsdaily.com/2018/03/13/immunomedics-inc-immu-shares-sold-by-nexthera-capital-lp.html.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.